Lantus (insulin glargine) and Levemir (insulin detemir) Lantus and Levemir will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 October 2006 for the treatment of patients with diabetes. Lantus and Levemir will be used to maintain a basic insulin level and are expected to reduce the incidence of episodes of low blood-sugar levels compared with current therapy. Both drugs have been recommended for Type 1 Diabetes. Lantus has also been recommended for Type 2 Diabetes.
It is estimated that around 110,000 people will begin treatment with Lantus or levemir in the first full year of listing for the treatment of Type 1 and Type 2 diabetes.
Lantus is a long-acting, peakless basal insulin, used once a day to help control blood glucose levels for a full 24 hours. It is used by people with type 1 or type 2 diabetes who are six years old or older.
Lantus provides : Smooth and consistent insulin release. Reduced risk of hypoglycaemia. Steady 24 hour activity, which allows for one injection of Lantus per day. Flexibility. Mimics normal basal insulin secretion.
By registering with Lantus Navigator you will have access to telephone support by nurse consultants, information on using Lantus and managing your diabetes. For more information, please call 1800 LANTUS (1800 526 887).
Smooth and consistent insulin release.